There’s an entire segment (possibly, a majority) of the world population that would suffer a mental collapse if they discovered the truth.
Instead of searching for truth, they grab the jack-boot (of injection) ever more tightly in a vain psychotic hope their executioner will spare them.
That sentiment is supported by reports of second injections … even after the fist one is nearly fatal.
Which brings us to the biotech sector.
Analysis:
In the first thirty minutes of trading, we can see SPBIO, has made a new daily low with inverse LABD (below), making a new daily high.
That price action helps confirm (no guarantee) that we’ve pivoted at the 23.6%, level as discussed earlier in this update.
If SPBIO continues to erode from here, it’s indicating potential for a sustained, possibly dramatic move lower.
If the reports found on alternate sites (here and here) are true, biotech is destroying its own customer base; most of that base may be gone by the end of the year:
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
MRNA has not been around long from a trading standpoint.
Long enough though, for a quick 1,000% price increase so insiders can bail with huge profits; leaving the bag to the uninformed retail ‘investor’.
SeekingAlpha:
A quick search of the proletariat at SeekingAlpha turns up several ‘analysis’ articles on MRNA.
Specific links won’t be provided.
We’re not going to provide links and justify the brainwashed, everybody’s thinking the same thing mentality that seems to permeate the site’s ‘presenters’.
Incredibly, the last three articles on MRNA do not contain a single price chart. It’s hard to say where a company is headed without consulting the truth; that is, price action.
Search MRNA if you like but be prepared to hold your nose.
To be fair, the comment section on the latest Moderna post does have a few frustrated souls attempting to get the word out.
It’s a futile effort to argue … no one can tell the difference and the sane person looks to be insane.
Spending time either creating articles for SeekingAlpha or commenting on such, is a waste. It’s a distraction (like attempting to locate the source of the ‘speck’) from the real work at hand.
However, it does provide a fantastic insight into the current group-think.
Biotech Sector:
The last update on SPBIO, had it testing and reversing at the Fibonacci 23.6%, level.
The index could continue lower without delay. Or, as is typical market behavior, it will attempt to re-establish some kind of upward move.
Updates on the sector to be forthcoming based on price action.
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
With atmosphere just 1% of Earth …. that’s one-percent; somehow we get clouds forming that have a strangely familiar ‘metallic sheen’ to them just like you see after a high level ‘spraying’ right here on Earth.
The plus side; As we get closer to the fall (regular flu season) … just months away, everyone’s going to have a fantastic opportunity to find out what there’re really made of.
Bravery’s like a muscle. It needs to be exercised often.
In a way, it’s nice to see that mediocrity, stupidity and laziness may be set for a thorough house cleaning.
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
For argument’s sake, let’s just say we find out the speck came from Dubuque, Iowa.
There, problem solved.
Does that make anyone’s life any different?
Well, maybe for those in Dubuque but probably not anywhere else.
Meanwhile, the objective of constant distraction and obfuscation has accomplished its goal; ‘missed opportunities’.
That’s what it’s all about; has been for millennia.
Who decides what goes to press anyway?
Enough said.
We’re not going to get distracted with the carnival sideshow but stay focused on shorting biotech (not advice, not a recommendation).
Market Analysis:
The overall markets are up anywhere from +0.50% – 1.50%.
On the other side, we have biotech SPBIO; down -0.65%, with leveraged inverse fund LABD, up around +3.94%.
The original forecast chart for SPBIO (hourly inverted), has been updated to show where price action is at this juncture.
We’ll include all (three) charts for an easy visual on how the short (via LABD), is progressing
Newest chart first:
Price action looks like its finished testing and is now rising into the resistance area shown as the dotted line (chart above).
Reminder: It’s a forecast and it can fail (or morph) at any time.
However, thus far price action’s adhering well to probability behavior under the ‘spring’ set-up conditions.
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
However, this go-round looks to be especially poignant.
Stay tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The forecast chart has been annotated to show where price action is now.
Biotech (SPBIO), and inverse fund LABD, are in a deep test. A little deeper than expected … but not enough to invalidate the set-up.
As of this post, price action is near the support line that’s just below the “Test” label.
Of course, the expectation is for this test to hold and for LABD to reverse back higher into the dynamic move shown; not advice, not a recommendation.
Fundamentals:
It seems like each day provides new insight into the disaster that is biotech.
This just out:
If you have been injected, The Red Cross says your blood is not wanted; your antibodies have been destroyed.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
First, the daily chart with the familiar trendlines
The magenta arrow shows, down-thrust has diverged. Today closed lower but thrust energy was (nearly) nonexistent.
The right side trend is still unknown.
More contact points are needed. However, inverse fund LABD has shown consistent trend angles (above) at various points throughout its sideways, corrective move.
Taking the SPBIO hourly chart and inverting, gives a more accurate picture; we see the Wyckoff set-up:
This type of price action is high probability. Not perfect, but still potentially 75% – 80%, effective or higher.
The fact that inverse tracking fund LABD accelerated upward into the close adds weight, we’re potentially at the end of the correction.
The fundamental backdrop continues to implode.
The plan for world control (through speck injected depopulation) is out in the open now. No doubt.
Amandha Vollmer has this update on the decades long, mass hypnosis.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Then, way back to “Reminiscences“, published in 1923.
As a reminder, we’re looking at biotech (SPBIO) from the perspective of being short the market.
The primary vehicle for that short, is highly leveraged inverse fund, LABD.
The last update gave a hint at the desired timeframe.
If the markets are in the process of reversing, ultimately going to the long awaited (since 2009), final draw-down (i.e. crash), then a likely bottom would occur where they (almost) always occur; during the third week of October.
In a nutshell, that’s the time frame.
Conversely, price action is the final arbiter. If biotech winds up effectively saying ‘not now’, well then, it has the final say.
Back to ‘Entries & Exits’.
One of the traders highlighted in the book (in addition to Weis), was William Doane; former Head Technician for Fidelity.
His timeframe is much longer than the typical market participant. He, like Weis are looking at monthly, quarterly and yearly charts.
That fact in and of itself, provides an edge.
One of the main take-aways from his section was (paraphrasing):
‘The first correction is the hardest. If you can get through that, it’s typically smooth sailing from then on’.
The biotech short via LABD (not advice, not a recommendation) may be at that point now. Painful to watch but necessary.
Next, we go to ‘Reminiscences’.
Those who have read the book, know all about ‘Turkey’; Mr. Partridge.
As the book states, he was much older than the rest who frequented the brokerage. Also, he did not appear to be that active in the markets (thus minimizing his transactions). He was interested in the big move.
The admonition from Partridge, was: ‘Don’t lose your position’. Don’t exit out, expecting a pull-back … that ultimately never comes.
So, we have two examples; three if you include Weis that begin from the very long time-frames and work inward.
Now, on to the market:
The long term, Quarterly analysis has already been done; linked here.
The chart in the link, is from last quarter and since then, (during this quarter), we’ve made new lows.
On the fundamental side, evidence is building by the day on what the ‘speck’ protection is all about.
If you’re really interested in the big picture, here’s a link to a five-plus hour presentation that spells it all out.
Momentum indicators MACD, on the Monthly and Weekly remain in a downtrend.
Using IBB, as the proxy for Quarterly momentum (not enough data for SPBIO), the indicator is flat.
Momentum’s in favor of (maintaining) a short position; not advice, not a recommendation.
The monthly chart of SPBIO (inverted), has price action coming back to former resistance (now support). This is normal market behavior.
Recall, that on the downside, if there is some kind of ‘event’, markets can slice through apparent support levels with ease.
With that in mind, on the inverted chart above, the next major ‘resistance’ level may or may not be of consequence.
Summary:
Each trading week is important.
However, next week will likely a pivotal one; providing more information on whether to maintain short or exit and stand aside; not advice, not a recommendation.
Stay Tuned
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
Note: The last two links do not verify the veracity of the referenced material. Be advised.
Momentum is building for some kind of ‘tipping point’.
We may be there now.
We’re looking for an avalanche of reports whose combined (fundamental and technical) effect is catastrophic implosion of the biotech sector.
Market Analysis:
The chart speaks for itself. It’s obvious biotech has reversed and could be in serious trouble.
The inverse fund LABD is up a stiff 10.5%, as of this post:
We may or may not have a trading channel as shown.
The right side trendline will need more confirmation. As always, anything can happen and the nascent move could fall apart.
However, what is known:
SPBIO’s (and LABD’s) pivot was called ‘to the day’.
The “Iceberg” notation references this report, where the probability of SPBIO downside at that juncture was presented.
That analysis was correct. SPBIO never looked back.
Positioning:
Our ‘project’ position remains open (not advice, not a recommendation). The correct stance under current circumstances is to let price action take LABD higher.
As Livermore said nearly a century ago, the hard part now is to ‘sit tight’. Let the market determine when the move has ended.
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
